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Introduction
============

Malignant tumors of the parotid gland are characterized by their low incidence rate (1% to 3% of all head and neck cancers) and marked histopathological heterogeneity \[[@REF1]\]. Approximately 70% of the malignant tumors of the major salivary glands are in the parotid gland \[[@REF2]\]. Tumors in the submandibular and parotid regions are not quite as accessible. For these tumors, fine-needle aspiration (FNA) is the preferred method of biopsy. Several studies have now demonstrated that FNA is a reliable technique achieving a diagnostic result in 88% to 98% of biopsies \[[@REF3]-[@REF5]\]. Superficial parotidectomy preserving the facial nerve has remained the recommended treatment modality, while adjuvant treatment and cervical lymph node removal are usually reserved for advanced stage, high-grade histology tumors \[[@REF6]-[@REF8]\]. Factors influencing the oncological outcome of these tumors include the level of histological diversity, primary tumor status, regional nodal involvement, and adjuvant use of chemo-radiotherapy. Our study aims to describe the clinicopathological behavior of malignant parotid tumors and explore the oncological outcomes related to survival from a tertiary care cancer hospital in Pakistan.

Materials and methods
=====================

We conducted a retrospective analysis of 209 patients with a malignant parotid tumor who received treatment from January 2004 to December 2014 at Shaukat Khanum Memorial Cancer Hospital and Research Center in Lahore, Pakistan.

All patients presented to the head and neck clinic after histological confirmation by FNA cytology. Imaging such as computerized tomography or magnetic resonance imaging was utilized to assess the local extent of the disease as well as the nodal status.

A head and neck multi-disciplinary team discussed each patient before making a final decision on treatment.

Surgical procedures performed were superficial parotidectomy (nerve sparing), completion parotidectomy (operation following previous incomplete procedure), radical parotidectomy (nerve sacrificing), extended radical parotidectomy (sacrificing adjacent muscles and soft tissue such as skin depending upon local extension of the disease). Neck dissection as part of the procedure was offered to those with tumor size of \>3 cm, clinically involved lymph nodes, nodes found to be positive during intraoperative frozen sections, and high-grade malignancy.

Similarly, adjuvant radiotherapy was offered to those with high-grade malignancy, close or positive resection margins, and tumor size \>4 cm, and positive lymph nodes.

Variables such as patient age, gender, clinical and pathological staging, final histology, grading, type of treatment modality used, the extent of neck dissection, margin status, and site of recurrence were recorded and evaluated. We have grouped patients into early (T1-T2) and locally advanced (T3-T4) disease stages to avoid dispersing the data. Patients were also categorized into clinically node negative and positive as well as pathologically node negative and positive groups to analyze survival.

Data were analyzed using IBM SPSS Statistics for Windows, Version 20.0 (released 2011, IBM Corp. Armonk, NY). Kaplan Meier curves were used to analyze survival data.

The study was reviewed by the Institutional Review Board, and the exemption was granted by the Ethical Review Committee of Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan.

Results
=======

We retrospectively analyzed the medical records of 209 patients diagnosed with malignant parotid neoplasms. There were 119 men and 94 women. One hundred sixty-four patients were primarily treated with surgery or surgery followed by radiotherapy in our hospital while 39 patients underwent operations in a different facility but were given adjuvant treatment in our clinic. The median patient age at diagnosis was 40 years. The median follow-up was 24 months. Table [1](#TAB1){ref-type="table"} shows the clinical and pathological staging, histology, type of parotidectomy, and treatment modality used. Clinical tumor stage showed cT1 (49 cases), cT2 (65 cases), cT3 (31 cases), and cT4 (64 cases). Pathological classification showed pT1 (43 cases), pT2 (60 cases), pT3 (38 cases), and pT4 (23 cases).

Eighty-two patients received superficial parotidectomy, 71 patients received complete parotidectomy, nine patients received radical parotidectomy, and two patients received extended radical parotidectomy.

Forty-one patients received neck dissection as part of the procedure, and 36 of those were classified as pN+ while five were classified pN0.

Histology revealed mucoepidermoid carcinoma to be the most common malignancy (with a 50% incidence rate) followed by adenoid cystic carcinoma (10.5%) and adenocarcinoma (9.6%). Only 23 patients received surgery alone while 141 patients received surgery followed by radiotherapy. Thirty-nine patients underwent operations in a different facility, and these patients received postoperative radiotherapy in the presence of adverse conditions such as a close/positive margin, high-grade malignancy, tumor size \>4 cm, facial nerve involvement, and extra-parenchymal extension. The median postoperative radiotherapy dose was 60 Gy on the parotid gland and 55 Gy on the neck. Adjuvant chemotherapy was used in select patients who had gross lymph nodal involvement.

The five-year and 10-year overall survival was 68% and 45%, respectively, for all the patients (Figure [1](#FIG1){ref-type="fig"}). The five-year and 10-year survival rates were 78% and 54%, respectively, for those treated exclusively in our hospital (Figure [2](#FIG2){ref-type="fig"}). Variables, which have statistical significance on survival, were age (categorized as either \<50 or \>50 years; p = 0.029), grade (high vs low; p \< .001), pathological nodal involvement (pN0 vs pN+; p \< .001), and pathological tumor size (pT1-2 vs pT3-4; p \< 0.001) as shown in Table [2](#TAB2){ref-type="table"} and Figures [3](#FIG3){ref-type="fig"}-[5](#FIG5){ref-type="fig"}. Multivariate analysis showed age above 50 years, high grading, advanced pathological stage, and nodal involvement to be significant factors affecting survival (Table [3](#TAB3){ref-type="table"}). The 5-year survival of patients who were previously treated outside our hospital has not shown promising results in terms of survival (Figure [6](#FIG6){ref-type="fig"}).

###### Clinico-pathological characteristics.

  ---------------------------------- ----- ------
                                       N     %
  Age                                       
  \<50 years                         141   67.5
  \>50 years                         68    32.5
  Sex                                       
  Male                               115   55
  Female                             94    45
  cT                                        
  1                                  49    23.4
  2                                  65    31.1
  3                                  31    14.8
  4                                  64    30.6
  pT                                        
  1                                  43    26.2
  2                                  60    36.5
  3                                  38    23.1
  4                                  23    14
  cN0                                156   74.6
  cN+                                53    25.3
  pN0                                128   78
  pN+                                36    22
  Surgical treatment type                   
  Superficial parotidectomy          82    50
  Completion parotidectomy           71    43.2
  Radical parotidectomy              9     5.4
  Extended radical parotidectomy     2     1.2
  Histology                                 
  Mucoepidermoid carcinoma           105   50.2
  Adenoid cystic carcinoma           27    12.9
  Adenocarcinoma                     22    10.5
  Squamous cell carcinoma            13    6.2
  Acinic cell carcinoma              11    5.2
  Carcinoma Ex-pleomorphic adenoma   9     4.3
  Others                             22    10.5
  Treatment modality                        
  Surgery                            23    11
  Surgery + Adjuvant radiotherapy    141   67.4
  Adjuvant radiotherapy              39    18.6
  Adjuvant chemotherapy              6     2.8
  Neck dissection                           
  Yes                                41    19.6
  No                                 168   80.3
  ---------------------------------- ----- ------

###### Prognostic factors affecting survival outcome.

ND: Neck dissection; cN0: Clinically negative neck nodes; cN+: Clinically positive/palpable nodes neck; pN0: Pathologically negative neck nodes; pN+: Pathologically positive neck nodes; PNI: Perineural invasion; PORT: Post operative radiotherapy.

  ----------------------------- ------------------- -------------------- ------------
                                5-Year Survival     10-Year Survival     p-value  
  Age \< 50 years               82%                 58%                  .029
  \>50 years                    62%                 51%                  
  Male                          77%                 51%                  0.57
  Female                        77%                 61%                  
  c T1-T2                       86%                 79%                  \<0.0001
  c T3-T4                       43%                 14%                  
  p T1-T2                       88%                 71%                  \<0.0001
  p T3-T4                       58%                 25%                  
  c N0                          77%                 65%                  \<0.0001
  c N+                          33%                 0%                   
  p N0                          85%                 73%                  \<0.0001
  p N+                          55%                 0%                   
  ND: Yes                       74%                 74%                    \<0.0001
  ND: No                        85%                 79%                  
  Grade                                                                   
  High                          56                  30                   \<0.001
  Low                           87                  70                   
  PNI                                                                     
  Yes                           56%                 0%                   0.08
  No                            77%                 58%                  
  Extra-parenchymal extension                                            0.150
  Yes                           66%                 0%                   
  No                            75%                 54%                  
  Adjuvant PORT                                                          0.250
  Yes                           76%                 49%                  
  No                            90%                 90%                  
  ----------------------------- ------------------- -------------------- ------------

###### Multivariate analysis affecting survival outcome.

  -------------------------------- --------- --------------
  Variable                         p-value   Hazard Ratio
  Age (\<50 years vs \>50 years)   0.127     1.8
  Grade (Low vs High)              0.05      2.1
  pT1-2 vs pT3-4                   0.02      2.6
  pN0 vs pN+                       0.01      2.7
  -------------------------------- --------- --------------
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Discussion
==========

Most salivary neoplasms originate in the parotid gland, while minor salivary gland and submandibular gland neoplasms are much less common. A low incidence combined with histological heterogeneity poses a challenge in evaluating survival and oncological outcomes \[[@REF9]\].

Age and gender have been postulated as prognostic factors in studies published by Malata, et al., Pohar, et al., Koul, et al., Jouzdani, et al., and Lima, et al., in contrary to a study by Mercante, et al. reporting no difference in survival \[[@REF10]-[@REF15]\]. Based on our findings, age is an important prognostic factor in terms of survival (p = 0.029), but no significant difference was found as far as gender is concerned (Figure [3](#FIG3){ref-type="fig"}).

Harbo, et al. established a relationship related to tumor stage and histological classification \[[@REF16]\]. A retrospective study on 152 patients with parotid tumors found a statistically significant difference in survival based on tumor stage. The survival rate for Stage I and II tumors was 65% and 50%, respectively, and falls to 9% in Stage IV patients \[[@REF17]\]. The prognosis for survival in histologically well-differentiated tumors (52%) was also better than the prognosis associated with poorly differentiated lesions (19%). Our experience showed that survival related to malignant parotid tumors depends upon cT (p \< 0.0001), pT (p \< 0.0001), cN (p \< 0.0001), pN (p \< 0.0001), histology (p \< 0.001), and ND (p \< 0.0001), which is comparable to other retrospective series as demonstrated by Lima, et al., Terhaard, et al., and Stenner, et al. \[[@REF14],[@REF17],[@REF18]\]. Thus, patients with clinical and pathological tumor sizes \>T2, high-grade histology, clinical and pathological nodal involvement, and perineural involvement have worse five-year and 10-year survival (Figure [4](#FIG4){ref-type="fig"} and Figure [5](#FIG5){ref-type="fig"}). The role of adjuvant radiotherapy is reported to improve survival according to Armstrong, et al. and Mendenhall, et al. \[[@REF19]-[@REF20]\], but our results indicated no such benefit (Figure [2](#FIG2){ref-type="fig"}). Postoperative radiation therapy may reduce the risk of loco-regional failure, thus decreasing the risk of damage to the facial nerve in cases of loco-regional failures. Clear evidence of a dose-response is lacking in this rare disease, and the dose of 60 Gy in daily 2 Gy fractions represents a practical consensus. Developments in radiotherapy technique such as intensity modulated radiotherapy have been applied to parotid treatment \[[@REF21],[@REF22]\]. A careful analysis of our data has shown that patients with adverse features were candidates for adjuvant radiotherapy, which may explain the poor survival outcome in these individuals. As the only tertiary care referral cancer hospital, we cannot refuse patients who have been previously treated elsewhere with inadequate resections. Of 209 malignant parotid tumor patients, 39 had been accepted for adjuvant treatment after surgery in a facility outside of our hospital. The five-year survival of these individuals was only 25% (Figure [6](#FIG6){ref-type="fig"}). In our experience, this poor outcome is mostly attributed to open biopsies outside contaminating the surrounding bed by spillage of tumor cells, fragmented nature of the resected specimen, delayed presentations for adjuvant treatment post-primary surgery and attempting inoperable tumors leaving behind gross residual disease by outside surgeons. Similarly, the role of extraparenchymal extension affecting survival has been described by Klussmann, et al., but its role is not statistically evident according to our results. This may be due to only a small number of patients having extraparenchymal extension, and larger sample size may highlight its role in survival \[[@REF23]\].

Conclusions
===========

We evaluated oncological outcomes of malignant parotid salivary gland tumors by identifying the prognostic factors affecting survival. Advanced age, high-grade histology, increased size (\>T2) and clinicopathological nodal involvement adversely affect overall survival. Adjuvant radiotherapy, however, has not resulted in improved survival particularly in the background of advanced disease.
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